A series of 4-phenoxy quinoline-based mevalonolactone derivatives have been synthesized and evaluated as 3-hydroxy-3-methylglutaryl CoA reductase （HMG CoA reductase） inhibitors.One member of this series,（4R,6S）-6-{（E）-2-[6-fluoro-7-chloro-4-（4-fluorophenoxy-quinoline）-3-yl-]-ethenyl}-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-one （3d）,showed more potent activity than rosuvastatin or pitavastatin to inhibit the rat HMG CoA reductase in vitro.This compound was selected for the extensive preclinical development as a potential hypocholesterolemic candidate.
